Yahoo Web Search

Search results

1. Kymera Therapeutics, Inc.

   NasdaqGM: KYMR

   35.70

   Add to watchlist

   Sign in to add to watchlist

   Sign In

   +0.38 (+1.08%)

   At close: Wed. May 22, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Pre-Market Time

   Full chart

   • 1D
   • 5D
   • 1M
   • 6M
   • YTD
   • 1Y
   • MAX

   • Open	35.10
     High	36.24
     Low	34.36

   • Mkt Cap	2.19B
     P/E (TTM)	N/A
     Div & Yield	N/A & N/A

   • Prev. Close	35.32
     52 Wk. Low	9.60
     52 Wk. High	45.31

   More about KYMR

   Top stories

   • KYMR
     +1.08%

   Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think

   Yahoo Finance · 3 weeks ago

   

   • KYMR
     +1.08%

   Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

   Yahoo Finance · 3 weeks ago

   

   • KYMR
     +1.08%

   Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript

   Yahoo Finance · 3 weeks ago

   

   Related stocks

   • NRIX
     Nurix Therapeutics, Inc.
     NRIX
     16.11
     +1.07%
   • RLAY
     Relay Therapeutics, Inc.
     RLAY
     7.53
     -0.40%
   • CCCC
     C4 Therapeutics, Inc.
     CCCC
     5.80
     +0.69%
   • RVMD
     Revolution Medicines, Inc.
     RVMD
     39.77
     +0.28%
   • ITOS
     iTeos Therapeutics, Inc.
     ITOS
     17.86
     -0.94%

   More on Yahoo Finance

2. finance.yahoo.com › quote › KYMRKymera Therapeutics, Inc. (KYMR) Stock Price, News, Quote ...

   finance.yahoo.com › quote › KYMR

   • Cached

   Find the latest Kymera Therapeutics, Inc. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing.

3. investors.kymeratx.comKymera Overview | Kymera Therapeutics, Inc.

   investors.kymeratx.com

   • Cached

   May 2, 2024 · Investor Relations. Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

4. www.kymeratx.comRevolutionary Medicines Catalyzed by Protein Degradation ...

   www.kymeratx.com

   • Cached

   Dec 10, 2023 · Kymera is a biotech company that develops medicines using targeted protein degradation, a novel modality that can address a wide range of diseases. Learn more about Kymera's pipeline, team, and vision to reinvent medicine.

5. www.google.com › finance › quoteKymera Therapeutics Inc (KYMR) Stock Price & News - Google ...

   www.google.com › finance › quote

   • Cached

   Get the latest Kymera Therapeutics Inc (KYMR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

6. finance.yahoo.com › news › kymera-therapeuticsKymera Therapeutics to Present New Clinical Data from the ...

   finance.yahoo.com › news › kymera-therapeutics

   • Cached

   May 14, 2024 · WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

7. Images

   • 
   • 
   • 
   • 

   View all

8. www.globenewswire.com › news-release › 2024/05/22Kymera Therapeutics Presents New Preclinical Data for

   www.globenewswire.com › news-release › 2024/05/22

   • Cached

   17 hours ago · WATERTOWN, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...

9. investors.kymeratx.com › news-events › press-releasesPress Releases | Kymera Therapeutics, Inc.

   investors.kymeratx.com › news-events › press-releases

   • Cached

   Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2. WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), will report first quarter 2024 ...